Sanofi and POZEN sign a license agreement for the commercialization of omeprazole and aspirin combination product.

FDA inspections reveal possible inaccurate sterility testing.

Following passage in the California Assembly, the California State Senate passes legislation to specify requirements for dispensing biosimilars.

Otsuka's planned acquisition bolsters its pipeline in oncology and adds fragment-based drug-discovery technology.

Rockwell Collins will sell Kaiser Optical Systems to Endress+Hauser.

Meda will acquire Acton Pharmaceuticals.

BioReliance opens Clearance Services Laboratories in Maryland for downstream bioprocessing studies.

Endo will acquire Boca Pharmacal in multimillion dollar deal.

Agilent Technologies opens multimillion dollar Spectroscopy Technology Innovation Center in Australia.

FDA approves BD Simplist product ondansetron injection, an injectable antiemetic.

Merck & Co gets FDA approval to manufacture bulk varicella at its in Durham, North Carolina for use in chickenpox and shingles vaccines.

Zealand will join efforts with Eli Lilly to design and develop therapeutic peptides for Type 2 diabetes and obesity.

CEO of Waters Corporation will retire within in the next two years.

Capsugel plans to acquire Bend Research to enhance its bioavailability-enhancement capabilities.

Baxter and Coherus Biosciences colaborate to develop and commercialize a biosimilar version of etanercept for Europe, Canada, and, Brazil.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Novartis Ilaris, an interleukin-1 beta inhibitor, treats active system juvenile idiopathic arthritis.

Prequalification of Sanofi Pasteur?s Menomune vaccine makes it eligible for purchase by United Nations agencies.

Sobi's application for Orfadin oral suspension has been validated by EMA.

Hospira has initiated a voluntary nationwide user-level recall of Aminosyn II, due to a foreign particle included in the injection port.

BioReliance updates Big Blue Mouse Assay service to meet OECD test requirements.

The new director general has stepped into the European generic and biosimilar medicines industries at a challenging time when the trade association is facing numerous priority issues on the European agenda.

The new subcutaneous formulation of Herceptin can be administered six times faster than the standard intravenous formulation.

FDA has issued a safety alert after a patient with multiple sclerosis in Europe developed a rare and serious brain infection known as progressive multifocal leukoencephalopathy following treatment with Gilenya (fingolimod).

There has been a notable shift in interest for life-science companies over recent months from institutional investors investing through the public markets, but any plans to release further capital will rely on first-rate R&D.

PDA/FDA regulatory conference promotes a commitment to quality.

Pharma eyes biologics production in Brazil as the government begins to recognize the potential of these drugs.

Establishing a well-defined training program is a crucial activity for any biopharmaceutical organization.